{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:23:14Z","timestamp":1792754594020,"version":"4.5.0"},"reference-count":100,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,11,11]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>In systemic lupus erythematosus (SLE), adaptive immunity is activated by the stimulation of innate immunity, leading to the development of autoreactive T cells and activation and differentiation of B cells. Cytokine signalling plays an essential role in the pathogenesis and progression of this disease. In particular, the differentiation and function of CD4+ T cell subsets, which play a central role in SLE pathology, are significantly altered by cytokine stimulation. Many cytokines transmit signals via the Janus-activated kinase (JAK)-STAT pathway, but there is no one-to-one correspondence between cytokine receptors and JAK\/TYK2. Multiple cytokines activate JAK\/TYK2, and multiple JAK\/TYK2 molecules are simultaneously activated by a single cytokine. Therefore, the modulation of the JAK-STAT pathway has the potential to control immune responses in SLE. Although several JAK\/TYK2 inhibitors are currently undergoing clinical trials, more selective drugs that can target cytokine signals according to the specific pathology of the disease are required. TYK2 inhibitors, which are involved in the signal transduction of type I interferon and interleukin-12\/23 pathways and are linked to disease susceptibility genes in SLE, may have the potential to fine-tune the differentiation and function of immune cells, particularly CD4+ T cells.<\/jats:p>","DOI":"10.1136\/rmdopen-2024-005072","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T11:35:16Z","timestamp":1735644916000},"page":"e005072","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Fine-tuning SLE treatment: the potential of selective TYK2 inhibition"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct05858645","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05556265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04877990","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04857034","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03252587","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03920267","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05617677","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05620407","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03252587","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-2360","authenticated-orcid":false,"given":"Yurie","family":"Satoh-Kanda","sequence":"first","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"2025090313115489000_10.4.e005072.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297"},{"key":"2025090313115489000_10.4.e005072.2","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025090313115489000_10.4.e005072.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0677-6"},{"key":"2025090313115489000_10.4.e005072.4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101921-042422"},{"key":"2025090313115489000_10.4.e005072.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2025090313115489000_10.4.e005072.6","doi-asserted-by":"crossref","unstructured":"Morand EF , Furie R , Tanaka Y , et al . TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382. doi:10.1056\/NEJMoa1912196","DOI":"10.1056\/NEJMoa1912196"},{"key":"2025090313115489000_10.4.e005072.7","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/acr.24740","article-title":"Patterns of Medication Use in Systemic Lupus Erythematosus: A Multicenter Cohort Study","volume":"74","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313115489000_10.4.e005072.8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003432","article-title":"Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study","volume":"17","author":"Pujades-Rodriguez","year":"2020","journal-title":"PLoS Med"},{"key":"2025090313115489000_10.4.e005072.9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/rheumatology\/kead348","article-title":"Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality-a national cohort study","volume":"63","author":"Frodlund","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313115489000_10.4.e005072.10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13075-022-02869-9","article-title":"Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study","volume":"24","author":"Abe","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090313115489000_10.4.e005072.11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.02.004","article-title":"Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study","volume":"112","author":"Zen","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2025090313115489000_10.4.e005072.12","first-page":"350","article-title":"Increased risk of infection-related death in SLE","volume":"16","author":"Onuora","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313115489000_10.4.e005072.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025090313115489000_10.4.e005072.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2025090313115489000_10.4.e005072.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025090313115489000_10.4.e005072.16","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025090313115489000_10.4.e005072.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2025090313115489000_10.4.e005072.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2025090313115489000_10.4.e005072.19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-020-00978-5","article-title":"T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update","volume":"23","author":"Chen","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313115489000_10.4.e005072.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.013"},{"key":"2025090313115489000_10.4.e005072.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00726-8"},{"key":"2025090313115489000_10.4.e005072.22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"2025090313115489000_10.4.e005072.23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313115489000_10.4.e005072.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01510-4"},{"key":"2025090313115489000_10.4.e005072.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.01.014"},{"key":"2025090313115489000_10.4.e005072.26","doi-asserted-by":"crossref","first-page":"102870","DOI":"10.1016\/j.jaut.2022.102870","article-title":"Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies","volume":"132","author":"Li","year":"2022","journal-title":"J Autoimmun"},{"key":"2025090313115489000_10.4.e005072.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.58"},{"key":"2025090313115489000_10.4.e005072.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.004"},{"key":"2025090313115489000_10.4.e005072.29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/1744666X.2021.1976146","article-title":"Clinical relevance of T follicular helper cells in systemic lupus erythematosus","volume":"17","author":"Nakayamada","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313115489000_10.4.e005072.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.05.012"},{"key":"2025090313115489000_10.4.e005072.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00693-5"},{"key":"2025090313115489000_10.4.e005072.32","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/art.39020","article-title":"Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity","volume":"67","author":"Choi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025090313115489000_10.4.e005072.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075319","article-title":"Circulating TFH subset distribution is strongly affected in lupus patients with an active disease","volume":"8","author":"Le Coz","year":"2013","journal-title":"PLoS One"},{"key":"2025090313115489000_10.4.e005072.34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008146"},{"key":"2025090313115489000_10.4.e005072.35","first-page":"909","article-title":"Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production","volume":"24","author":"Zhang","year":"2015","journal-title":"Lupus (Los Angel)"},{"key":"2025090313115489000_10.4.e005072.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088441","article-title":"T Follicular Helper Cells and Regulatory B Cells Dynamics in Systemic Lupus Erythematosus","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS ONE"},{"key":"2025090313115489000_10.4.e005072.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500368"},{"key":"2025090313115489000_10.4.e005072.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11754-0"},{"key":"2025090313115489000_10.4.e005072.39","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090222-102834"},{"key":"2025090313115489000_10.4.e005072.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.04.006"},{"key":"2025090313115489000_10.4.e005072.41","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003991","article-title":"Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"key":"2025090313115489000_10.4.e005072.42","doi-asserted-by":"publisher","DOI":"10.1038\/nature20810"},{"key":"2025090313115489000_10.4.e005072.43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/intimm\/dxad041","article-title":"Peripheral helper T cells, mavericks of peripheral immune responses","volume":"36","author":"Yoshitomi","year":"2024","journal-title":"Int Immunol"},{"key":"2025090313115489000_10.4.e005072.44","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/rheumatology\/keac646","article-title":"TGF-\u03b23 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus","volume":"62","author":"Shan","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313115489000_10.4.e005072.45","doi-asserted-by":"publisher","DOI":"10.1038\/nri2295"},{"key":"2025090313115489000_10.4.e005072.46","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/823085","article-title":"Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new","volume":"2012","author":"Alunno","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2025090313115489000_10.4.e005072.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1805717115"},{"key":"2025090313115489000_10.4.e005072.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601765"},{"key":"2025090313115489000_10.4.e005072.49","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2019.1693545"},{"key":"2025090313115489000_10.4.e005072.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.07.021"},{"key":"2025090313115489000_10.4.e005072.51","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adk1643","article-title":"Age-associated CD4+ T cells with B cell-promoting functions are regulated by ZEB2 in autoimmunity","volume":"9","author":"Goto","year":"2024","journal-title":"Sci Immunol"},{"key":"2025090313115489000_10.4.e005072.52","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156"},{"key":"2025090313115489000_10.4.e005072.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.012"},{"key":"2025090313115489000_10.4.e005072.54","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/740619","article-title":"The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity","volume":"2010","author":"Lieberman","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"2025090313115489000_10.4.e005072.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.01.038"},{"key":"2025090313115489000_10.4.e005072.56","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.60"},{"key":"2025090313115489000_10.4.e005072.57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13075-021-02535-6","article-title":"Therapeutic potential of targeting Tfr\/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study","volume":"23","author":"Miao","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313115489000_10.4.e005072.58","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/art.41457","article-title":"Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukin\u20102 Through Transcriptional Regulation in Systemic Lupus Erythematosus","volume":"73","author":"Hao","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025090313115489000_10.4.e005072.59","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12020-024-03753-z","article-title":"Assessing the effectiveness of Interleukin-2 therapy in experimental type 1 diabetes","volume":"85","author":"Luo","year":"2024","journal-title":"Endocrine"},{"key":"2025090313115489000_10.4.e005072.60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903158107"},{"key":"2025090313115489000_10.4.e005072.61","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.1165","article-title":"Efficacy, safety and the lymphocyte subsets changes of low-dose IL-2 in patients with systemic lupus erythematosus: A systematic review and meta-analysis","volume":"12","author":"Su","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2025090313115489000_10.4.e005072.62","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090313115489000_10.4.e005072.63","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/mr\/roac140","article-title":"Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease","volume":"38","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2025090313115489000_10.4.e005072.64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41584-024-01152-2","article-title":"Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy","volume":"20","author":"Ghodke-Puranik","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313115489000_10.4.e005072.65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025090313115489000_10.4.e005072.66","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201364"},{"key":"2025090313115489000_10.4.e005072.67","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00826-z"},{"key":"2025090313115489000_10.4.e005072.68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"2025090313115489000_10.4.e005072.69","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"2025090313115489000_10.4.e005072.70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"EBioMedicine"},{"key":"2025090313115489000_10.4.e005072.71","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025090313115489000_10.4.e005072.72","unstructured":"Sotyktu CTD module 2.6. bristol myers squibb K. K. 2022. Available: https:\/\/www.pmda.go.jp\/drugs\/2022\/P20221006002\/670605000_30400AMX00412_H100_1.pdf"},{"key":"2025090313115489000_10.4.e005072.73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203756"},{"key":"2025090313115489000_10.4.e005072.74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01510"},{"key":"2025090313115489000_10.4.e005072.75","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"2025090313115489000_10.4.e005072.76","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02546-6"},{"key":"2025090313115489000_10.4.e005072.77","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025090313115489000_10.4.e005072.78","first-page":"1518","article-title":"Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2025090313115489000_10.4.e005072.79","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216576","article-title":"Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors","volume":"80","author":"Meyer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025090313115489000_10.4.e005072.80","unstructured":"U.S. Food and Drug Administration . Center for drug evaluation and research: nda 203,214 tofacitinib for rheumatoid arthritis, addendum to primary clinical review. Edited by Department of Health and Human Services, Silver Spring, MD; 2012. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203214Orig1s000Approv.pdf"},{"key":"2025090313115489000_10.4.e005072.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00767-7"},{"key":"2025090313115489000_10.4.e005072.82","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41423-019-0320-3","article-title":"JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis","volume":"17","author":"Nocturne","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025090313115489000_10.4.e005072.83","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761"},{"key":"2025090313115489000_10.4.e005072.84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2025090313115489000_10.4.e005072.85","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00018-024-05234-y","article-title":"Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling","volume":"81","author":"Bodega-Mayor","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"2025090313115489000_10.4.e005072.86","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059246"},{"key":"2025090313115489000_10.4.e005072.87","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025090313115489000_10.4.e005072.88","doi-asserted-by":"crossref","unstructured":"Kahlenberg JM , Sanz I , Wu C , et al . Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study. Arthritis Rheumatol 2022;74. doi:10.1136\/annrheumdis-2023-eular.1719","DOI":"10.1136\/annrheumdis-2023-eular.1719"},{"key":"2025090313115489000_10.4.e005072.89","unstructured":"Gillooly K , Zhang Y , Yang X , et al . BMS-986165 is a highly potent and selective allosteric inhibitor of TYK2, blocks IL-12, IL-23 and Type I Interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease. Arthritis Rheumatol 2016;68."},{"key":"2025090313115489000_10.4.e005072.90","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025090313115489000_10.4.e005072.91","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.40180","article-title":"Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients","volume":"69","author":"Kubo","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090313115489000_10.4.e005072.92","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","article-title":"Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis","volume":"9","author":"Parodis","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025090313115489000_10.4.e005072.93","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224795"},{"key":"2025090313115489000_10.4.e005072.94","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac332","article-title":"Scoring personalized molecular portraits identify Systemic Lupus Erythematosus subtypes and predict individualized drug responses, symptomatology and disease progression","volume":"23","author":"Toro-Dom\u00ednguez","year":"2022","journal-title":"Brief Bioinformatics"},{"key":"2025090313115489000_10.4.e005072.95","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa006","article-title":"Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases","volume":"4","author":"Sloan","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2025090313115489000_10.4.e005072.96","doi-asserted-by":"crossref","first-page":"425","DOI":"10.36849\/JDD.7098","article-title":"Open-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)","volume":"22","author":"Alsukait","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"2025090313115489000_10.4.e005072.97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2025090313115489000_10.4.e005072.98","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02607-1"},{"key":"2025090313115489000_10.4.e005072.99","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab685"},{"key":"2025090313115489000_10.4.e005072.100","first-page":"1420","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus (Los Angel)"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-005072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:12:10Z","timestamp":1756930330000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-005072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":100,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/rmdopen-2024-005072"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-005072","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}